Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06010563 · ClinicalTrials.gov registry record · NA
VenusP-Valve Pivotal Study (PROTEUS STUDY)
A NA study of Pulmonary Regurgitation, sponsored by Venus MedTech (HangZhou).
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06010563: Recruiting NA study of Pulmonary Regurgitation, sponsored by Venus MedTech (HangZhou).
NCT06010563 is a NA study of Pulmonary Regurgitation that is actively recruiting participants, run by Venus MedTech (HangZhou). The registered enrollment target is 60 participants, below the 118-participant average among 4 other Pulmonary Regurgitation trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06010563, a NA study of Pulmonary Regurgitation, is actively recruiting participants, sponsored by Venus MedTech (HangZhou).
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective, multi-center, non-randomized interventional study to evaluate the safety and effectiveness of the VenusP-ValveTM System in patients with native right ventricular outflow tract (RVOT) dysfunction. Post procedure, a clinical visit will be scheduled at pre-discharge, 30 days, 6 months, 12 months, and annually thereafter to 10 years. About 60 subjects will be enrolled in this study. Data analysis will be performed after all enrolled subjects complete 6-month follow-up and the primary endpoint analysis report will be submitted to FDA for PMA approval.
Primary Outcome
Freedom from procedure or device related mortality at 30 days
Conditions Studied
Interventions
- DEVICE Transcatheter pulmonary valve implantation (TPVI)
- DEVICE VenusP-ValveTM System
Study Locations (1)
California
- Venusmedtech of America - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-06-11 |
| Est. Completion | 2034-08-30 |
| Phase | NA |
What NCT06010563 shows while recruiting
NCT06010563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 118-participant average among 4 other Pulmonary Regurgitation trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Pulmonary Regurgitation appearing as the primary indexed condition, and to 2 interventions - of which Transcatheter pulmonary valve implantation (TPVI) is the first listed.
NCT06010563 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06010563 about?
NCT06010563 is a clinical study titled "VenusP-Valve Pivotal Study (PROTEUS STUDY)". A prospective, multi-center, non-randomized interventional study to evaluate the safety and effectiveness of the VenusP-ValveTM System in patients with native right ventricular outflow tract (RVOT) dysfunction. Post procedure, a clinical visit will be scheduled at pre-discharge, 30 days, 6 months, ...
What is the current status of trial NCT06010563?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-06-11. Estimated completion is 2034-08-30.
What conditions does trial NCT06010563 study?
This clinical trial studies the following conditions: Pulmonary Regurgitation.
What interventions are being tested in trial NCT06010563?
The interventions under investigation include: Transcatheter pulmonary valve implantation (TPVI) (DEVICE), VenusP-ValveTM System (DEVICE).
Who is sponsoring clinical trial NCT06010563?
This trial is sponsored by Venus MedTech (HangZhou), which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06010563 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI